Item 9 Labs (OTCMKTS:INLB) & Artivion (NYSE:AORT) Head-To-Head Contrast

Item 9 Labs (OTCMKTS:INLB) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Item 9 Labs and Artivion, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Item 9 Labs	0	0	0	0	0.00
Artivion	1	0	7	0	2.75

Artivion has a consensus price target of $44.83, suggesting a potential upside of 55.78%. Given Artivion’s stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Item 9 Labs.

Risk & Volatility

Item 9 Labs has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Profitability

This table compares Item 9 Labs and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Item 9 Labs	N/A	N/A	N/A
Artivion	-0.67%	6.07%	2.93%

Institutional & Insider Ownership

86.4% of Artivion shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Item 9 Labs and Artivion”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Item 9 Labs	N/A	N/A	N/A	($0.20)	N/A
Artivion	$441.33 million	3.18	$9.77 million	($0.07)	-411.14

Artivion has higher revenue and earnings than Item 9 Labs. Artivion is trading at a lower price-to-earnings ratio than Item 9 Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Artivion beats Item 9 Labs on 10 of the 11 factors compared between the two stocks.

About Item 9 Labs

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.